Endocrine Abstracts

Introduction: Prolactinoma is the most common type of pituitary adenoma, but it still presents difficulties in management especially in women who present some particularities hence the interest of our study.¹

Material and method: This is a retrospective, descriptive study including 14 patients, hospitalized in the Endocrinology-Diabetology-Nutrition Department at CHU-Mohammed-VI-Oujda, between 2016–2022. The statistical analysis was performed by SPSS version 21 software.

Results: The mean age of the patients was 35.9±13.2 years, of which 55.5% were in the menopausal period. The mode of revelation was mainly presented by a tumor syndrome in 57.1% of cases, isolated signs of hyperprolactinemia in 42.9%, while infertility was observed in 35.7%. Galactorrhea was present in 64.3% of women, cycle disorders in 78.6%, and decreased libido in 28.6%. The mean prolactin level was 353.4 ng/ml, associated with a gonadotropic deficit in 64.3%. Morphologically, macroprolactinomas predominated with 57.1% of cases. All patients benefited from medical treatment with dopaminergic agonists, and surgery in 21% of cases, which allowed recovery of gonadotropic function in 85% of cases, and the achievement of pregnancy in 28.5% of cases.

Discussion-conclusion: Dopaminergic agonists remain the effective first-line treatment for prolactinomas, allowing both the restoration of gonadal function and the achievement of pregnancy, which remains however of delicate management requiring a codified management².

References: 1. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Chanson P, et al. Best Pract Res Clin Endocrinol Metab. 2019. PMID: 31326373

2. Glezer A, Bronstein MD. Prolactinomas in pregnancy: considerations before conception and during pregnancy. Pituitary. Springer US; 2019